In pre-ruminant calf oral rehydration adjuncts, tannic acid of veterinary API grade is incorporated as an astringent to reduce uncontrolled hydro-electrolytic secretion in scour management. The addition ratio is typically 0.4–1.2% w/w of the dry granule mass, with the upper end reserved for formulations that do not contain bismuth subsalicylate or kaolin-pectin colloidal competing surfaces. A water-soluble carrier system comprising dextrose monohydrate, sodium chloride, trisodium citrate dihydrate, and potassium chloride is pre-blended in a 600 L top-drive high-shear granulator at an impeller tip speed of 5–8 m/s. Tannic acid is added during the final 30–45 s of dry mixing to reduce exposure to the subsequent 8–12 min wet massing cycle. Purified water is metered at 1.5–2.0 kg/min through a ported spray nozzle until 2–3 mm granules are formed. Production-scale observation on high-shear lines indicates consistent granulation endpoints are better controlled by amperometric load than by fixed time; a 10–14% rise in impeller load from dry-mix baseline is used as the endpoint. Wet mass is discharged into a fluid-bed dryer and dried at inlet air temperature 55–65 °C to a product temperature not exceeding 40 °C, with final loss on drying between 2.0–3.5%. Dried granules are passed through an 0.8 mm sieve and transferred to a 2,000 L double-cone blender. For tablet-grade material, sodium croscarmellose and magnesium stearate are added and mixed for 8–10 min. Compression is performed on a 27-station rotary press at 12–18 kN main compression, target hardness 60–100 N, friability below 1.0%, and disintegration below 15 min in 37 °C water. Terminal product types are 1 g, 2 g, and 5 g low-density polyethylene/aluminum/polyethylene terephthalate sachets, 250 mg and 500 mg rapidly dispersible scored tablets, and 100 g bulk tubs for farm-level volumetric dosing. Compliance is anchored to 21 CFR 211.110 for in-process blending uniformity, 21 CFR 225 where the product is registered as a medicated feed adjunct, USP <905> for uniformity of dosage units, USP <1216> for tablet friability, and USP <701> for disintegration.

What Limits Sterile Filtration of Tannic Acid–Containing Intramammary Infusion Solutions?

Aseptic processing rather than terminal steam sterilization is preferred because autoclaving at 121 °C for 15 min accelerates gallic acid release and darkens the solution. Tannic acid is included at 0.05–0.2% w/v in a buffered aqueous vehicle containing sodium citrate and citric acid adjusted to pH 3.5–4.5, below the oxidation threshold where quinone polymers precipitate. The solution is prepared in a 316L stainless-steel jacketed compounding vessel at 40–45 °C under an agitator speed of 300–500 rpm, then cooled to 20–25 °C before passage through an 0.45 µm polyethersulfone prefilter and an 0.22 µm PES sterilizing-grade membrane at a maximum differential pressure of 2.0 bar. Membrane capacity is a critical operational boundary: polyphenol adsorption can reduce recovered solute by 5–15% if the first 200–300 mL of filtrate is not recirculated, and published data for tannic acid–specific membrane capacity remains limited. Filterability must therefore be validated per batch, and membrane integrity testing is conducted before and after filtration per ASTM F838-20. Terminal product types are 10 mL pre-sterilized low-density polyethylene intramammary syringes with smooth cannula tips, packed in units of 12 or 24. Compliance follows 21 CFR 211, USP <71> sterility testing, USP <85> bacterial endotoxin testing, and VICH GL18 residual solvent control. Injectable presentations are confined to local instillation; intravascular administration is contraindicated because tannic acid precipitates plasma proteins and is not supported as a systemic parenteral route.

Because equine pastern dermatitis requires sustained contact with exudative skin without systemic absorption, tannic acid is dispersed in a hydrophobic ointment base at 1.0–5.0% w/w, with the lower range applied when zinc oxide is present to avoid excessive particulate load and possible metal-tannate interaction. The API is air-jet milled to a D₉₀ below 50 µm before incorporation to reduce grittiness in topical films. White petrolatum and anhydrous lanolin are melted in a jacketed ointment vessel at 70–75 °C, cooled to 50–55 °C with continuous slow-sweep agitation, and the tannic acid fraction is added through a 150 µm vibratory sieve. Butylated hydroxytoluene at 0.05–0.2% w/w may be incorporated as a lipophilic antioxidant to limit color change associated with oxygen exposure. The semi-solid mass is passed twice through a stainless-steel roller ointment mill with a rear gap of 100 µm and a front gap of 30–50 µm, then deaerated under vacuum at −0.8 bar for 15–20 min. Terminal product types are 15 g and 30 g aluminum tubes with internal epoxy-phenolic lacquer and 50 g and 250 g high-density polyethylene jars. Compliance is governed by USP <795> for nonsterile compounding, 21 CFR 211 for commercial manufacturing, and ISO 13320-1:2020 for particle size distribution by laser diffraction.

Co-processing Tannic Acid with Montmorillonite in Post-Weaning Piglet Premixes

Dry co-grinding of tannic acid with montmorillonite is performed to reduce segregation in low-inclusion gut-health premixes for weaned piglets. The active fraction is adjusted to 250–500 g/t complete feed, equivalent to 0.025–0.050% w/w, while the premix itself is carried on pre-gelatinized wheat flour and calcium carbonate with a micro-doser setting of 50 g per 100 kg final mix. The process begins with a 5 kg micro-ingredient paddle mixer pass: tannic acid is first blended with montmorillonite at a 1:1 ratio for 10–15 min, then this intermediary is added to a 2,000 L twin-shaft paddle mixer with a fill level of 65–70% and mixed for 8 min until the coefficient of variation drops below 5% across ten sampling ports. Because tannic acid is hygroscopic and will cake at storage relative humidity above 60%, terminal packaging is performed in a humidity-controlled room at 35–40% RH and 18–22 °C. If incoming moisture exceeds 5.0%, pre-drying in a fluid bed at 50 °C for 20 min is applied before final blending. Terminal product types are 1 kg, 5 kg, and 20 kg valve-bottom multiwall paper sacks with low-density polyethylene inner liners, or 25 kg drums for feed-mill addition. Compliance is aligned with 21 CFR 225.1 for medicated feed premises, EU Regulation 1831/2003 where the product is registered as a zootechnical feed additive, and 21 CFR 211.110 where the premix is classified as an intermediate. The operational boundary for feed-mill handling is avoidance of prolonged contact with unlined carbon-steel bins, because iron-tannate complexes can form blue-black deposits that reduce assay and compromise mixer cleanability.

Companion animal gastric astringent capsules containing tannic acid are filled after dry granulation to address cohesiveness and dust containment. The capsule composition is 25–50 mg tannic acid per size 3 hard gelatin capsule with microcrystalline cellulose as diluent and 0.5% w/w sodium stearyl fumarate as lubricant. The powder is compacted on a roller compactor at roll force 6–10 kN/cm, roll speed 4–8 rpm, and screen mesh 0.8 mm to produce granules with bulk density 0.35–0.50 g/cm³ and Carr index below 25. Granules are filled on a dosator-type capsule machine at 60,000 capsules/h, with fill weight monitored every 15 min by automatic checkweighing. Residual moisture is held below 5.0% to avoid gelatin cross-linking from any residual aldehyde fraction in the polyphenol raw material. Terminal product types are 10-count and 30-count polyvinyl chloride/aluminum blister cards and 100-count high-density polyethylene bottles with desiccant canister. Compliance is governed by 21 CFR 211, USP <905>, and USP <1174> for powder flow measurement; dissolution testing may be referenced to USP <711> when a discriminatory medium is validated. The main incompatibility is the combination of tannic acid with free iron or ferric salts in the excipient system, which creates intense blue-black discoloration; microcrystalline cellulose with controlled iron content is therefore preferred.

When Tannic Acid Is Added to Poultry Drinking Water Soluble Powders, pH and Metal-Ion Content Determine Solution Stability

Solution instability is governed by three interrelated variables: final water pH, dissolved hardness ions, and residence time in stock solution. Product formulation uses 0.05–0.20 g/L drinking water after dilution, with a dry soluble powder concentration of 0.1–0.4% w/w tannic acid on anhydrous citric acid, sodium chloride, and low-moisture dextrose carriers. Production dry blending occurs in a 500 L twin-shell blender at 70–80% fill for 15–20 min, with intensive bar activated for the final 5 min. At the farm, the powder is drawn through a venturi eductor into a 316L stainless-steel intermediate tank at 20–25 °C; recirculating product flow of 4 m/s at the bottom drain prevents sedimentation of insoluble tannate complexes. The critical processing boundary is pH: above pH 5.5, oxidative polymerization to quinone derivatives reduces assay recovery by more than 15% within 4 h, and at water hardness above 150 mg/L CaCO₃, calcium tannate precipitation reduces filterability through nipple drinkers. Cleaning-in-place after batch use requires 1% citric acid solution at 60 °C to remove persistent tannate films from tank walls and piping. Terminal product types are 50 g, 100 g, and 1 kg aluminium/polyethylene sachets and 10 kg drums. Compliance is tied to EU Regulation 1831/2003 for feed additive status, 21 CFR 225.1 for premix CGMP, and potable water quality per WHO Guidelines for Drinking-water Quality, 4th edition. Published data for tannic acid–specific recirculation and precipitate recovery in hard water is limited; validation must include worst-case water hardness and pH trials rather than relying only on controlled laboratory vehicles.